Every 10-Q that Palisade Bio Inc (PALI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PALI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALI filings page.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing PALI-2108 for inflammatory bowel disease, advancing from Phase 1 into global Phase 2 programs (ASCENTRA-UC and planned ASCENTRA-CD). In June 2026, the FDA cleared an IND for the ASCENTRA-UC Phase 2 trial, with first patient enrollment expected in the second half of 2026.
For the three months ended June 30, 2026, the company reported $0.5 million of license revenue, all from a milestone under the Newsoara co-development agreement. Research and development expenses rose to $7.4 million and general and administrative expenses to $4.8 million, driven largely by higher headcount, program spending on PALI-2108, and significantly higher stock-based compensation. Net loss for the quarter was $10.6 million, and $20.2 million for the first six months of 2026.
Cash, cash equivalents and restricted cash totaled $125.2 million at June 30, 2026, down modestly from $133.4 million at year-end 2025. Management states this balance is sufficient to fund operations through key Phase 2 efficacy readouts in UC and CD into early 2028. The company continues to disclose a longstanding material weakness in internal control over financial reporting related to segregation of duties and formalized close processes, though it believes its financial statements are fairly presented.
Palisade Bio, Inc. reported a larger quarterly loss as it ramps development of its lead IBD drug candidate, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss widened to $9.6 million from $2.2 million a year earlier, driven by higher research and development and general and administrative spending. Research and development expenses rose to $6.4 million, reflecting increased clinical trial and manufacturing activity for PALI-2108 and higher stock-based compensation. General and administrative costs increased to $4.4 million, also largely from stock-based compensation and higher legal fees. The company generated $1.1 million of other income from money market investments following a large equity raise in 2025. Palisade ended the quarter with $132.6 million in cash, cash equivalents and restricted cash and believes this will fund key Phase 2 trials through efficacy readouts in ulcerative colitis and Crohn’s disease. Management still reports a material weakness in internal control over financial reporting and is pursuing remediation.
Palisade Bio (PALI) reported Q3 2025 results, highlighting lower operating spend and a major post‑quarter financing that strengthened liquidity. Operating expenses fell to $2.9 million from $3.6 million a year ago as research and development declined to $1.4 million, while general and administrative was $1.5 million.
The company posted a Q3 net loss of $2.9 million and a nine‑month net loss of $7.9 million. Cash and cash equivalents were $5.2 million at September 30, 2025, down from $9.8 million at year‑end, with net cash used in operations of $7.7 million for the nine months. Total assets were $7.0 million and stockholders’ equity was $3.2 million.
After quarter‑end, Palisade closed an underwritten equity offering on October 2, 2025 for $138 million in gross proceeds. Management concluded this significantly increases working capital and removes substantial doubt about continuing as a going concern for one year from issuance of these financial statements. During Q3, a July warrant‑exercise inducement brought in $3.9 million gross and created 8.64 million replacement warrants. Shares outstanding were 149,003,210 as of November 5, 2025; 9,119,152 shares were outstanding as of September 30, 2025.
Palisade Bio, Inc. reported interim results showing clinical progress on its lead candidate, PALI-2108, while facing tightened liquidity. The company completed dosing of 89 subjects across SAD, MAD, FE and a UC cohort in its Phase 1 study and announced positive results for the SAD/MAD/FE cohorts on May 27, 2025 and for the UC cohort on August 7, 2025. Management plans a Phase 1b cohort for fibrostenotic Crohn's disease and intends Phase 2 programs; an IND for the U.S. is anticipated in the first half of 2026.
Financially, Palisade had $5.4 million in cash and equivalents as of June 30, 2025, an accumulated deficit of $141.0 million, and recognized a net loss of $2.78 million for the quarter and $5.01 million for the six months ended June 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern for one year without additional financing. Subsequent to quarter-end, a July 2025 warrant inducement closed, generating approximately $3.9 million gross proceeds.